Botox doesn’t stop your face from drooping as you get older — everyone’s face sags the same amount over time, no matter how often you get injections.
Scientific Claim
In a 15-year computational simulation, facial sag index increases from 0.73–1.20 cm² at baseline to 1.19–1.32 cm² by year 15 across all botulinum toxin A treatment groups, with no significant differences between age at initiation or injection frequency, indicating BoNTA does not prevent soft-tissue descent.
Original Statement
“FSI ranged from 0.73–1.20 cm² at baseline to 1.19–1.32 cm² at year 15. Across all measures, differences between age cohorts and injection frequencies were small and not sustained over time.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The claim describes simulated model outputs with defined metrics and no biological causation; definitive language is valid for the computational behavior.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether long-term BoNTA use alters the rate of facial soft-tissue descent compared to no treatment.
Whether long-term BoNTA use alters the rate of facial soft-tissue descent compared to no treatment.
What This Would Prove
Whether long-term BoNTA use alters the rate of facial soft-tissue descent compared to no treatment.
Ideal Study Design
Meta-analysis of 15+ year longitudinal studies using 3D facial imaging to quantify facial sag index in 8,000+ adults with documented BoNTA use versus controls, stratified by age at initiation and injection frequency.
Limitation: Variability in FSI measurement protocols across imaging systems.
Longitudinal Cohort StudyLevel 2bNatural progression of facial sagging over 15 years in individuals receiving BoNTA versus those who do not.
Natural progression of facial sagging over 15 years in individuals receiving BoNTA versus those who do not.
What This Would Prove
Natural progression of facial sagging over 15 years in individuals receiving BoNTA versus those who do not.
Ideal Study Design
Prospective cohort of 1,000 adults aged 25–45 with annual 3D facial scans for 15 years, comparing FSI changes in those receiving biannual/triannual BoNTA versus untreated controls, adjusting for weight change and gravity exposure.
Limitation: Cannot control for concurrent fillers or surgical lifts.
Randomized Controlled TrialLevel 1bCausal effect of BoNTA on facial sagging over time.
Causal effect of BoNTA on facial sagging over time.
What This Would Prove
Causal effect of BoNTA on facial sagging over time.
Ideal Study Design
Double-blind RCT of 300 adults aged 30–40 randomized to biannual BoNTA, triannual BoNTA, or placebo for 15 years, with primary endpoint: change in facial sag index via 3D photogrammetry at year 15.
Limitation: Ethical and logistical challenges in maintaining 15-year blinding and compliance.
Evidence from Studies
Supporting (1)
A 15-Year Computational Twin Modeling Study of Botulinum Toxin A Frequency and Age-Related Facial Aging.
Even if people started Botox early or got it often, their faces still sagged the same amount after 15 years — so Botox doesn’t stop the face from drooping over time.